Ex­clu­sive: J&J folds car­dio­vas­cu­lar and meta­bol­ic drug unit

John­son & John­son is wind­ing down its phar­ma di­vi­sion’s car­dio­vas­cu­lar and meta­bol­ic unit, End­points News has learned.

The de­ci­sion pri­mar­i­ly im­pacts the sales, mar­ket­ing and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER